Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: Results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia
| Autor: | C. Peschel, Martin Schuler, Walter E. Aulitzky, Karin Kolbe, H. Schönbohn, Christoph Huber, W. Bemb |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic Neutropenia Adolescent Fever Sialoglycoproteins medicine.medical_treatment Myelogenous Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Blood plasma medicine Animals Humans Prospective Studies Chemotherapy Leukopenia Interleukin-6 Tumor Necrosis Factor-alpha business.industry Interleukin-8 Cytarabine Hematology General Medicine Middle Aged medicine.disease Granulocyte colony-stimulating factor Dacarbazine Interleukin 1 Receptor Antagonist Protein Leukemia Myeloid Acute Leukemia Nimustine Vincristine Immunology Cytokines Interleukin-2 Female Mitoxantrone medicine.symptom business Febrile neutropenia Interleukin-1 |
| Zdroj: | Annals of Hematology. 71:161-168 |
| ISSN: | 1432-0584 0939-5555 |
| Popis: | Plasma levels of IL-1, IL-6, IL-8, IL1-RA, TNF alpha, and G-CSF were prospectively studied during 23 chemotherapy cycles of 20 patients suffering from acute myelogenous leukemia. Increased plasma levels of IL-6, IL-8, and G-CSF were observed in patients with febrile neutropenia and/or major infection. Plasma levels of IL-6, IL-1, TNF alpha and IL-1-RA measured 1 day before and 1 day after the onset of febrile episodes did not accurately predict the development of major infection. In contrast, IL-8 plasma levels were significantly higher in those patients who subsequently developed major infection. The question whether IL-8 plasma levels identify high risk or low risk patients with sufficient specificity and sensitivity has to be answered in large scale clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink